Mirro center logo
Return to Clinical Trials Search Results

A randomized phase III trial comparing an antibody-drug conjugate to Mirvetuximab in patients with FRa high expression and compared to investigators choice chemotherapy in FRa low expression. TREVI-OC-01

Phase

III

Recruitment Status

Current Studies